×
Hero Background

Renal Cancer Drug Companies

ID: MRFR/HC/5004-HCR
200 Pages
Rahul Gotadki
October 2025

Renal cancer, or kidney cancer, is a type of cancer that originates in the kidneys. Companies involved in renal cancer drug development focus on researching, developing, and manufacturing pharmaceuticals for the treatment of renal cell carcinoma (RCC) and other forms of kidney cancer. These companies play a critical role in advancing therapeutic options for individuals diagnosed with renal cancer.

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Top Industry Leaders in the Renal Cancer Drug Market

Renal Cancer Drug Key Companies

 

Latest Renal Cancer Drug Companies Update


Merck (MSD) FDA Priority Review granted for their sNDA for Welireg (a HIF-2α inhibitor) for previously treated RCC patients, with potential approval by January 17, 2024.Positive Phase III LITESPARK-005 trial results demonstrating Welireg's efficacy in extending progression-free survival (PFS) in advanced RCC patients.


Pfizer Expanded use of Bavencio (avelumab) with atezolizumab (Tecentriq) as first-line treatment for advanced RCC, as recommended by the National Comprehensive Cancer Network (NCCN) guidelines.


Invectys FDA Fast Track designation granted for their CAR-T therapy IVS-3001 for the treatment of RCC.


Bristol Myers Squibb Phase II clinical trial initiated for Nivolumab (Opdivo) in combination with Cabozantinib for treatment of papillary RCC.


List of Renal Cancer Drug Key Companies in the Market



  • Novartis AG (Switzerland)

  • Pfizer Inc. (US)

  • GlaxoSmithKline plc (UK)

  • Genentech Inc. (US)

  • Hoffmann-La Roche AG (Switzerland)

  • Cipla Limited (India)

  • Active Biotech AB (Sweden)

  • Amgen (US)

  • Bayer AG (Germany)

  • Bristol-Myers Squibb company (US)